Comparative efficacy of apalutamidedarolutamide and enzalutamidefor treatment of nonmetastatic castrate-resistant prostate cancer: Asystematic review and network meta-analysis.

CONCLUSION: Enzalutamide and apalutamide had similar and higher MFS rate in indirect comparison with darolutamide. In cases where AEs are concerning, darolutamide might be the preferred agent.
PMID: 32605736 [PubMed - as supplied by publisher]

Source: Urologic Oncology - June 27, 2020 Category: Urology & Nephrology Authors: Kumar J, Jazayeri S, Gautam S, Norez D, Alam MU, Tanneru K, Bazargani S, Costa J, Bandyk M, Ganapathi H, Koochekpour S, Balaji KC Tags: Urol Oncol Source Type: research